Navigation Links
PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015
Date:5/9/2011

INCLINE VILLAGE, Nev., May 9, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL, the Company) (NASDAQ: PDLI) today announced that it intends to offer, subject to market and other conditions, $135 million aggregate principal amount of new convertible senior notes due May 2015 under the Company's shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC) on May 9, 2011. The Company also expects to grant the underwriters a 13-day overallotment option to purchase up to an additional $20.25 million aggregate principal amount of notes on the same terms and conditions.

The notes will be senior unsecured obligations of the Company and interest will be payable semiannually. The notes may be converted, under certain circumstances, into cash and, if applicable shares of the Company's common stock. The notes contain a net share settlement feature so that upon conversion the Company will deliver cash equal to the lesser of the aggregate principal amount of notes to be converted and the Company's total conversion obligation, plus shares for the remainder, if any, of the conversion obligation. The interest rate, conversion price, offering price and other terms of the notes will be determined by the Company and the underwriters.

In connection with the offering of the convertible notes, the Company expects to enter into privately negotiated convertible note hedge transactions with counterparties that may include one or more of the underwriters (and/or their respective affiliates) (the "hedge counterparties").  The convertible note hedge transactions will cover, subject to customary anti-dilution adjustments, the number of shares of the Company's common stock that will initially underlie the convertible notes, and are intended to reduce the dilutive impact of the conversion feature of the notes on the Company’s outstanding shares of common stock.
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors
2. Sinobiopharma, Inc. Appoints New Director of Marketing
3. Enox Biopharma, Inc. Appoints Dr. John Rewcastle as CEO
4. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
5. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
6. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
7. Anesiva Announces Second Quarter 2008 Financial Results and Update
8. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
9. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
10. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
11. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... -- Research and Markets has announced the ... & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market ... The global molecular biology enzymes market ... expected to grow at a CAGR of 13.74% to ... & reagents find applications in a large number of ...
(Date:8/22/2014)... Angeles (PRWEB) August 22, 2014 ... age-defying products, is in the spotlight again. Nerium ... cream and its NeriumFirmTM Body Contouring Cream to ... by Backstage Creations during the 66th Primetime Emmy® ... patented NAE-8® extract, third-party clinical trials show that ...
(Date:8/22/2014)... “Our nation's healthcare system is broken, ... Furthermore, every governmental and professional entity that has ... of unorganized dysfunction shares in that enormous blame. ... as a device to use in an effort ... have accumulated through the years leading to the ...
(Date:8/21/2014)... PA & Rockville, MD (PRWEB) August 21, 2014 ... (ITI) is making progress in its development of ... to Japanese red cedar pollen. Phase IC studies began ... a real solution to hay fever. , The Japanese ... over 35 million people in Japan. Mountain Cedar pollen ...
Breaking Biology Technology:Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 2Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 3Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 2Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 35 Great Mistakes in Healthcare and How to Fix Them by Dr. Ira Williams 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4
... Combination of Panzem(R) NCD and Avastin(R) May ... 28 EntreMed, Inc.,(Nasdaq: ENMD ), ... treatment of cancer and inflammatory diseases, today,announced ... Phase 2 multi-center,study combining Panzem(R) NCD with ...
... PARIS, January 28 Sanofi-aventis announced,today that ... approved for marketing in Japan by the ... prevention of venous thromboembolism (VTE) in patients,undergoing ... as total hip,replacement, total knee replacement and ...
... Inc.,(NYSE: FRX ), Forest Laboratories Holdings, Ltd., ... GmbH announced that they have filed a second,lawsuit ... of Delaware against,additional companies for infringement of U.S. ... Forest,s Namenda(R) product. The defendants,named in the lawsuit ...
Cached Biology Technology:EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study 2EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study 3EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study 4Clexane(R)/Lovenox(R) Approved in Japan 2Clexane(R)/Lovenox(R) Approved in Japan 3Clexane(R)/Lovenox(R) Approved in Japan 4Clexane(R)/Lovenox(R) Approved in Japan 5Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KgaA File Additional Lawsuit Against Several Companies for Patent Infringement 2
(Date:8/22/2014)... tea polyphenols are strong antioxidants and can ... spinal cord neurons against oxidative stress? Jianbo ... Hospital of Liaoning Medical University, China discovered ... stress and inhibit neuronal apoptosis, indicating green ... spinal cord neurons under oxidative stress. The ...
(Date:8/22/2014)... American consumers will finally be able to purchase fuel ... as zero-emissions vehicles, most of the cars will run ... that contributes to global warming. , Now scientists at ... uses an ordinary AAA battery to produce hydrogen by ... through two electrodes that split liquid water into hydrogen ...
(Date:8/21/2014)... Ga. An international team of scientists including researchers from ... Brassica napus commonly known as canolain the journal Science ... the plant, which is used widely in farming and industry. ... its native Europe, but the winter crop is increasingly cultivated ... its naturally low levels of saturated fat and rich supply ...
Breaking Biology News(10 mins):Stanford scientists develop a water splitter that runs on an ordinary AAA battery 2Stanford scientists develop a water splitter that runs on an ordinary AAA battery 3Canola genome sequence reveals evolutionary 'love triangle' 2
... HUNTSVILLE, TX (Feb. 21, 2012)-- An assistant ... Criminal Justice is working to unlock the mysteries ... play on criminal and antisocial behavior. "Biosocial ... behavior," said Dr. Brian Boutwell. "It involves aspects ...
... 2012A team of researchers has found a way to ... to be available, despite the potential attack of Xylella ... poses a significant threat to the California wine industry,s ... Laboratory (LANL), University of California at Davis (UCD), and ...
... prospective study of ethnic differences in the symptoms of ... background have more delayed language, communication and gross motor ... the Kennedy Krieger Institute concluded that subtle developmental delays ... severe symptoms develop. While the prevalence of autism ...
Cached Biology News:Are there biosocial origins for antisocial behavior? 2More grapes, less wrath: Hybrid antimicrobial protein protects grapevines from pathogen 2New study shows minority toddlers with autism are more delayed than affected Caucasian peers 2New study shows minority toddlers with autism are more delayed than affected Caucasian peers 3
... Tissue Array (MSTA) slides were designed to study ... from multiple species. Tissue slices from three ... which can then be treated as a single ... in situ hybridization. This format allows ...
... Clear yellow solution. In ... thimerosal, and other proprietary ... Diluent formulated to stabilize ... antibody conjugates at high ...
... used to predict the melting ... up to 3,200 bases, which ... primers and GC clamps for ... gel electrophoresis (DGGE), constant denaturing ...
... Mini-Sub cell GT cell and PowerPac basic power ... of nucleic acids in agarose gels. The Mini-Sub ... with cables and electrodes, a 7 x 7 ... casting gates, and two 1.5 mm fixed-height combs ...
Biology Products: